Dizal Pharmaceutical (Dizal Pharma) – a joint venture between state-owned SDIC Fund Management, Swedish drug maker AstraZeneca and Zytz Partners – has announced the completion of a $100-million round of financing led by Lilly Asia Ventures (LAV).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
